MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine, Drug Discovery, Development & Delivery
2024: The 2024 Biotech Graveyard
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON)*
Organization & Developments: Tracon
Parents
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON)*
Children
2018: Reader Inquiry: What's The Current Outlook For Tracon Pharmaceuticals? - Tracon Pharmaceuticals (NASDAQ:TCON)
2022: FDA granted Fast Track Designation (FTD) for the development of envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS)
2022: Revisiting Tracon Pharmaceuticals_ seekingalpha.com
Development of TRC105, a promising therapeutic that inhibits the growth of new blood vessels that supply tumors - angiogenesis
The NCI, NIH also is supporting the company’s research and development, which includes ongoing trials in prostate, bladder, and liver cancer.
Jumps
*Key People: Tracon
Finance & Acquisitions: Tracon